Subcommittee hears bill to allow over‑the‑counter ivermectin; proponents stress access, opponents urge caution

RICHMOND — The Senate health‑professions subcommittee considered SB545, which would allow over‑the‑counter sales of ivermectin in Virginia.

Sen. Cyphers framed the bill as a patient‑access measure, highlighting ivermectin’s long track record for parasitic conditions, its inclusion on the World Health Organization’s essential‑medicines list, and its low cost. The sponsor said states including Texas and Tennessee have passed similar laws.

Supporters at the hearing included clinicians and advocacy groups who described the drug as widely tolerated and useful for common parasitic infections and some dermatologic conditions. Dr. Sheila Furey (recorded in testimony as a proponent) and others said making labeled, human‑dose formulations available OTC would reduce cases where people purchase veterinary ivermectin and dose incorrectly.

At least one committee member and others expressed discomfort that the issue became politicized during the COVID‑19 pandemic and noted limited physician testimony against the bill. Senators also raised safety questions including neurological side effects and drug interactions with anticoagulants.

A motion to report the bill was made and seconded; the committee held a voice vote in favor. Committee members noted they expect technical review of labeling, dosing and pharmacy controls as the measure progresses.

What happens next: The bill was reported out of the subcommittee for further consideration in the Senate.